Ripretinib Demonstrates Impressive Efficacy, Durability in Heavily Pretreated KIT-Mutated Melanoma

Source: OncLive, December 2021

Filip Janku, MD, PhD, discusses the phase 1 study with ripretinib in patients with KIT-mutated or KIT-amplified melanoma.

The efficacy seen with ripretinib (Qinlock) in patients with KIT-mutated melanoma was higher than has been previously reported, according to Filip Janku, MD, PhD. Furthermore, the switch-control tyrosine kinase inhibitor (TKI) has elicited durable responses, even in patients who were heavily pretreated, making the drug a powerful tool for this patient population.

Investigators enrolled 26 patients with KIT-altered melanoma into this 2-part dose escalation/expansion study (NCT02571036). Patients were treated at the recommended phase 2 dose of 150 mg with daily ripretinib.

At the May 10, 2021, data cutoff, the confirmed overall response rate was 23% with 1 complete response and 5 partial responses. The median progression-free survival (PFS) was 7.3 months, with a median duration of response of 7.4 months.

READ THE ORIGINAL FULL ARTICLE